Esteban Figueroa

Dr. Esteban Figueroa

Facultad de Ciencias para el Cuidado de la Salud, Universidad San Sebastián, Santiago, Región Metropolitana, Chile
orcid
Academic Researcher, Faculty of Health Care Sciences, Univer...

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2016 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
EHEmilio A. Herrera
Emilio A. Herrera
FCFrancisca Cifuentes‐Zúñiga
Francisca Cifuentes‐Zúñiga
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
CVCristian Villanueva
Cristian Villanueva
CHCherie Hernández
Cherie Hernández
BKBernardo Krause
Bernardo Krause

6 March 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
CACristian R. Astorga
Cristian R. Astorga
AGAlejandro Gonzalez-Candia
Alejandro Gonzalez-Candia
ACAlejandro A. Candia
Alejandro A. Candia
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
DCDaniel Cañas
Daniel Cañas
EHEmilio A. Herrera
Emilio A. Herrera
Background: Chronic hypoxia and oxidative stress during gestation lead to pulmonary hypertension of the neonate (PHN), a condition characterized by abnormal pulmonary arterial reactivity and remodelling. Melatonin has strong antioxidant properties and improves pulmonary vascular function. Here, we aimed to study the effects of melatonin on the function and structure of pulmonary arteries from PHN lambs. Methods: Twelve lambs (Ovis aries) gestated and born at highlands (3,600 m) were instrumented with systemic and pulmonary catheters. Six of them were assigned to the control group (CN, oral vehicle) and 6 were treated with melatonin (MN, 1 mg.kg-1.d-1) during 10 days. At the end of treatment, we performed a graded oxygenation protocol to assess cardiopulmonary responses to inspired oxygen variations. Further, we obtained lung and pulmonary trunk samples for histology, molecular biology and immunohistochemistry determinations. Results: Melatonin reduced the in vivo pulmonary pressor response to oxygenation changes. In addition, melatonin decreased cellular density of the media and diminished the proliferation marker KI67 in resistance vessels and pulmonary trunk (p<0.05). This was associated with a decreased in the remodelling markers α-actin (CN 1.28±0.18 vs. MN 0.77±0.04, p<0.05) and smoothelin-B (CN 2.13±0.31 vs. MN 0.88±0.27, p<0.05). Further, melatonin increased vascular density by 134% and vascular luminal surface by 173% (p<0.05). Finally, melatonin decreased nitrotyrosine, an oxidative stress marker, in small pulmonary vessels (CN 5.12±0.84 vs. MN 1.14±0.34, p<0.05). Conclusion: Postnatal administration of melatonin blunts the cardiopulmonary response to hypoxia, reduces the pathological vascular remodelling, and increases angiogenesis in pulmonary hypertensive neonatal lambs. These effects improve the pulmonary vascular structure and function in the neonatal period under chronic hypoxia.

4 October 2019 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
AGAlejandro Gonzalez-Candia
Alejandro Gonzalez-Candia
ACAlejandro A. Candia
Alejandro A. Candia
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
EFElisenda Feixes
Elisenda Feixes
CGCristopher Gonzalez‐Candia
Cristopher Gonzalez‐Candia
EHEmilio A. Herrera
Emilio A. Herrera

22 October 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
AGAlejandro Gonzalez-Candia
Alejandro Gonzalez-Candia
PAPamela V. Arias
Pamela V. Arias
SASimón A. Aguilar
Simón A. Aguilar
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
RRRoberto V. Reyes
Roberto V. Reyes
EHEmilio A. Herrera
Emilio A. Herrera
Pulmonary arterial hypertension of newborns (PAHN) constitutes a critical condition involving both severe cardiac remodeling and right ventricle dysfunction. One main cause of this condition is perinatal hypoxia and oxidative stress. Thus, it is a public health concern for populations living above 2500 m and in cases of intrauterine chronic hypoxia in lowlands. Still, pulmonary and cardiac impairments in PAHN lack effective treatments. Previously we have shown the beneficial effects of neonatal melatonin treatment on pulmonary circulation. However, the cardiac effects of this treatment are unknown. In this study, we assessed whether melatonin improves cardiac function and modulates right ventricle (RV) oxidative stress. Ten lambs were gestated, born, and raised at 3600 m. Lambs were divided in two groups. One received daily vehicle as control, and another received daily melatonin (1 mg·kg−1·d−1) for 21 days. Daily cardiovascular measurements were recorded and, at 29 days old, cardiac tissue was collected. Melatonin decreased pulmonary arterial pressure at the end of the experimental period. In addition, melatonin enhanced manganese superoxide dismutase and catalase (CAT) expression, while increasing CAT activity in RV. This was associated with a decrease in superoxide anion generation at the mitochondria and NADPH oxidases in RV. Finally, these effects were associated with a marked decrease of oxidative stress markers in RV. These findings support the cardioprotective effects of an oral administration of melatonin in newborns that suffer from developmental chronic hypoxia.

1 June 2021 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
AGAlejandro Gonzalez-Candia
Alejandro Gonzalez-Candia
Aitor Caballero-RománAitor Caballero-Román
Aitor Caballero-Román
Cristina FornagueraCristina Fornaguera
Cristina Fornaguera
EEElvira Escribano
Elvira Escribano
EHEmilio A. Herrera
Emilio A. Herrera
Stroke is the second leading cause of death worldwide, estimated that one-sixth of the world population will suffer it once in their life. The most common type of this medical condition is the ischemic stroke (IS), produced by a thrombotic or embolic occlusion of a major cerebral artery or its branches, leading to the formation of a complex infarct region caused by oxidative stress, excitotoxicity, and endothelial dysfunction. Nowadays, the immediate treatment for IS involves thrombolytic agents or mechanical thrombectomy, depending on the integrity of the blood-brain barrier (BBB). A common stroke complication is the hemorrhagic transformation (HT), which consists of bleeding into the ischemic brain area. Currently, better treatments for IS are urgently needed. As such, the neurohormone melatonin has been proposed as a good candidate due to its antioxidant, anti-inflammatory, and neuroprotective effects, particularly against lipid peroxidation and oxidative stress during brain ischemia. Here, we proposed to develop intravenous or intranasal melatonin nanoformulation to specifically target the brain in patients with stroke. Nowadays, the challenge is to find a formulation able to cross the barriers and reach the target organ in an effective dose to generate the pharmacological effect. In this review, we discuss the current literature about stroke pathophysiology, melatonin properties, and its potential use in nanoformulations as a novel therapeutic approach for ischemic stroke.

14 November 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
RCRodrigo Castillo
Rodrigo Castillo
Jorge G. FaríasJorge G. Farías
Jorge G. Farías
Cristian Sandoval-VásquezCristian Sandoval-Vásquez
Cristian Sandoval-Vásquez
AGAlejandro Gonzalez-Candia
Alejandro Gonzalez-Candia
Esteban FigueroaEsteban Figueroa
Esteban Figueroa
Rodrigo CarrascoRodrigo Carrasco
Rodrigo Carrasco
In heart failure (HF) patients undergoing cardiac surgery, an increased activity of mechanisms related to cardiac remodeling may determine a higher risk of postoperative atrial fibrillation (POAF). Given that atrial fibrillation (AF) has a negative impact on the course and management of HF, including the need for anticoagulation therapy, identifying the factors associated with AF occurrence after cardiac surgery is crucial for the prognosis of these patients. POAF is thought to occur when various clinical and biochemical triggers act on susceptible cardiac tissue (first hit), with oxidative stress and inflammation during cardiopulmonary bypass (CPB) surgery being potential contributing factors (second hit). However, the molecular mechanisms involved in these processes remain poorly characterized. Recent research has shown that patients who later develop POAF often have pre-existing abnormalities in calcium handling and activation of NLRP3-inflammasome signaling in their atrial cardiomyocytes. These molecular changes may make cardiomyocytes more susceptible to spontaneous Ca2+-releases and subsequent arrhythmias, particularly when exposed to inflammatory mediators. Additionally, some clinical studies have linked POAF with elevated preoperative inflammatory markers, but there is a need for further research in order to better understand the impact of CPB surgery on local and systemic inflammation. This knowledge would make it possible to determine whether patients susceptible to POAF have pre-existing inflammatory conditions or cellular electrophysiological factors that make them more prone to developing AF and cardiac remodeling. In this context, the NLRP3 inflammasome, expressed in cardiomyocytes and cardiac fibroblasts, has been identified as playing a key role in the development of HF and AF, making patients with pre-existing HF with reduced ejection fraction (HFrEF) the focus of several clinical studies with interventions that act at this level. On the other hand, HFpEF has been linked to metabolic and non-ischemic risk factors, but more research is needed to better characterize the myocardial remodeling events associated with HFpEF. Therefore, since ventricular remodeling may differ between HFrEF and HFpEF, it is necessary to perform studies in both groups of patients due to their pathophysiological variations. Clinical evidence has shown that pharmacological therapies that are effective for HFrEF may not provide the same anti-remodeling benefits in HFpEF patients, particularly compared to traditional adrenergic and renin–angiotensin–aldosterone system inhibitors. On the other hand, there is growing interest in medications with pleiotropic or antioxidant/anti-inflammatory effects, such as sodium–glucose cotransporter 2 inhibitors (SGLT-2is). These drugs may offer anti-remodeling effects in both HFrEF and HFpEF by inhibiting pro-inflammatory, pro-oxidant, and NLRP3 signaling pathways and their mediators. The anti-inflammatory, antioxidant, and anti-remodeling effects of SGLT-2 i have progressively expanded from HFrEF and HFpEF to other forms of cardiac remodeling. However, these advances in research have not yet encompassed POAF despite its associations with inflammation, oxidative stress, and remodeling. Currently, the direct or indirect effects of NLRP3-dependent pathway inhibition on the occurrence of POAF have not been clinically assessed. However, given that NLRP3 pathway inhibition may also indirectly affect other pathways, such as inhibition of NF-kappaB or inhibition of matrix synthesis, which are strongly linked to POAF and cardiac remodeling, it is reasonable to hypothesize that this type of intervention could play a role in preventing these events.